Health

I read the inflation report the way I read a court docket: close up, suspicious of the fine print, and aware that a tidy headline can hide a messy reality.

BLS: prescription drug prices fell 1.5% in March, even as overall inflation jumped

The Bureau of Labor Statistics reported the CPI for All Urban Consumers rose 0.9% in March (seasonally adjusted) and was up 3.3% over the past year. Energy did the heavy lifting: energy rose 10.9% in March, with gasoline up 21.2%. That is the kind of spike that makes household budgets flinch.

Inside the same release, the medical care index decreased 0.2% in March, and the prescription drugs index decreased 1.5%. Meanwhile, physicians’ services rose 0.7% and hospital services rose 0.4%. Over the past year, the medical care index was up 3.1%.

So yes, there is good news. But it comes with the usual American paperwork attached.

Why a CPI win often does not feel like a win at the pharmacy counter

A national index can say prices fell while the pharmacy checkout still feels like a toll booth with a rotating cast of collectors. That is not a conspiracy. That is system design.

• The CPI is broad. It is not your receipt.
• It misses lived friction. It does not capture a drug getting bumped into a “please file an appeal” tier.
• It misses cost-shifting. Out-of-pocket costs can still rise depending on deductibles, formularies, network rules, and other fine print.

That is why a 1.5% monthly decline can coexist with people still paying the same or spending hours untangling coverage decisions.

The Orwell check: when the system calls a surcharge a “rebate”

Listen to the language. In health care, a barrier becomes a “safeguard,” a delay becomes “utilization management,” and money padded upstream becomes a “rebate” downstream. Everyone will claim the drug-price dip as proof their preferred machine works. Almost nobody will make the money trail legible.

The liberty ledger and the Paine test

Who gains freedom when drug prices fall? Patients, employers, taxpayers. Who loses freedom when the system stays opaque? Patients who cannot predict costs, doctors whose judgment gets second-guessed, families forced into rationing by finances rather than medicine.

The Paine test is simple: do lower prices expand liberty in real life, or do savings ricochet around the system while power stays concentrated in a locked room?

Guardrails that make relief real

If prices are easing, make the relief legible and durable:

• Sunlight: clearer disclosure of where drug spending goes, in plain language ordinary people can read.
• Competition: treat consolidation and contract games that block lower prices like a hidden tax on the sick.
• Privacy: modernize the plumbing without turning medical data into a temptation for overreach.

Congress, agencies, courts, and voters all have roles here: oversight that survives audits, rules that are narrow and reviewable, due process when coverage decisions become medical decisions. I’ll take the CPI’s 1.5% drop. I’m just not applauding until Americans stop paying a confusion premium for the privilege of staying alive.

I have seen this play before: a windowless committee room, coffee that tastes like toner, and a surveillance idea introduced as “modernization.” Paper shuffles. Acronyms march. Someone says “oversight” like it is a lullaby. And then your private life becomes a spreadsheet with a federal logo.

This time, the plot lands in health care. The Office of Personnel Management (OPM) is seeking ongoing access to detailed, identifiable health-claims data tied to federal workers, retirees, and their families. If you are among the more than 8 million people covered under the Federal Employees Health Benefits (FEHB) and Postal Service Health Benefits (PSHB) programs, this is not abstract. It is your prescriptions, your diagnoses, and the map of your bad days.

What OPM is asking for

Reported by CBS News and KFF Health News, OPM’s notice would require 65 insurance carriers to send monthly claims-level data to OPM, plus quarterly manufacturer rebate data. The notice labels the collection “service use and cost data,” and describes categories including medical claims, pharmacy claims, encounter data, and provider data.

CBS reports the notice did not instruct insurers to remove identifying details. Multiple experts told CBS they read the request as aiming for identifiable data, not merely de-identified trend lines.

OPM argues the goal is oversight and affordability. In its Paperwork Reduction Act notice, it cites HIPAA’s health oversight pathway as a basis for carriers to disclose protected health information to an oversight agency for authorized oversight activities.

CBS also reports the notice was posted and sent to insurers in December, comments closed in March, and OPM had not provided an update as of the report.

The Orwell check: “service use and cost data” is a euphemism

Translate the phrase. Claims data can reveal what treatment you sought, where you got it, how long the visit was, and which drugs you filled. Calling that “service use and cost data” makes a life story sound like printer ink.

The Paine test: liberty vs. centralized power

The Paine test is simple: does this expand liberty or concentrate power? Centralizing identifiable health information concentrates power. Even if today’s intent is good, the tool can be misused in politics, abused by a future administration, or breached by criminals.

CBS reports legal and policy experts raised concerns about whether the justification is specific enough under HIPAA standards, including the “minimum necessary” principle. That is not a nitpick. That is the bargain.

The liberty ledger and the tradeoff

Potential benefit: OPM gets a powerful dataset to analyze costs, utilization, and plan performance, which in theory could help push down waste and improve pricing.

Real cost: Enrollees take on risk. Identifiable claims data is leverage and exposure. Carriers also face compliance pressure and potential liability if information is shared and later breached, as CBS reports.

OPM’s published privacy materials on its Research and Oversight Repository (ROVR) describe using record-level identifiable data to build person-level longitudinal records across years and across plan changes, and note such data is generally not used for a specific individual except in cases like suspected fraud, waste, or abuse.

And one fact belongs in the header of every memo: CBS notes that in 2015 OPM disclosed a massive breach in which personal records of roughly 22 million people were stolen.

If OPM wants the vault keys, it should earn them in plain language: why identifiable data is necessary, how the collection is minimized, and what independent audits, strict access controls, logging, and retention limits will actually be enforced.

I have read enough government rate notices to recognize the vibe: warm copier toner, cold confidence, and a strong belief the public will not ask follow-up questions.

CMS released its Calendar Year 2027 Medicare Advantage and Part D Rate Announcement. Wall Street heard “more money.” Seniors heard “please do not change my plan again.” Taxpayers heard a familiar tab opening, payable on demand.

The headline number: 2.48% and about $13 billion

CMS says the finalized Medicare Advantage payment policies are projected to produce a net average increase of 2.48%, or over $13 billion in additional payments to Medicare Advantage plans in 2027.

CMS also says that if you account for the expected risk score trend in Medicare Advantage, driven by population changes and coding practices, the overall increase comes out to 4.98%.

Markets did what markets do. A Reuters report noted major insurer stocks jumped on April 7 after the announcement, with UnitedHealth, Humana, CVS, and Elevance moving up.

What changed (and what did not)

The real story lives in the fine print, where CMS tries to talk about integrity without picking a fight with every plan that has mastered the art of turning diagnoses into revenue.

• Risk adjustment model: CMS is continuing to use the 2024 Medicare Advantage risk adjustment model for 2027. It is not moving to the updated model it proposed in the advance notice, which would have been calibrated with more recent Original Medicare data. CMS frames this as giving the market more time to adjust after the phase-in of the 2024 model.
• Chart reviews: Starting in 2027, CMS is excluding diagnosis information from unlinked chart review records (diagnoses not tied to a specific encounter) from risk score calculations, with an exception for beneficiaries who switch from one Medicare Advantage organization to another.
• Audio-only: CMS is also finalizing the exclusion of diagnoses from audio-only encounters for risk score calculation.

The tradeoff: stability vs. clean receipts

Medicare Advantage is sold as choice. Sometimes it is. Sometimes it is a maze of prior authorization, narrow networks, and benefits that sparkle in October and quietly dim by March.

My centrist reality check: in a system serving tens of millions of older Americans, you cannot treat payment policy like a political mood ring. Wild swings invite plan exits and benefit cuts. But you also cannot keep sending more public money into a system if the oversight tools look like a 1997 civics textbook trying to regulate a 2026 revenue analytics department.

The Orwell check

CMS says the announcement “strengthens accountability” and supports “long-term sustainability.” Fine phrases. The question is whether they come with proof the public can actually see.

The liberty ledger

Seniors may gain stability. Plans and shareholders may gain, too. Taxpayers risk paying more without a clear, public, plan-by-plan receipt connecting dollars to outcomes. And when access to care depends on opaque internal processes and an appeal a senior does not know how to file, power is concentrated, not shared.

Guardrails before the next bump

If Medicare Advantage is getting paid more in 2027, the public should demand transparency that is readable, due process that is real, and oversight that people can trust. More money should come with more proof, out loud.

I found this story the way I find too many lately: in the paperwork. Under fluorescent lights, when a government building feels less like a public square and more like a library that lost its patience. The paper trail is the point now. Not the patients. Not the doctors. The forms.

What HHS says it is doing

This week, the Department of Health and Human Services (HHS), through its Office for Civil Rights (OCR), announced it is investigating thirteen states over abortion coverage mandates under the Weldon Amendment, a federal conscience provision tucked into spending law.

HHS OCR says it is investigating: California, Colorado, Delaware, Illinois, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Vermont, and Washington. The claim is not that these states banned abortion. The claim is that their insurance rules coerce certain health care entities to cover or pay for abortion against conscience, and that this coercion is discrimination barred by the Weldon Amendment.

The interpretation shift

HHS also says it has repudiated a prior (2021) position that excluded employers and plan sponsors from the set of protected “health care entities,” and it warned states not to rely on that older reading. Translation: the administration is widening who can claim the conscience shield, and it is doing it through a civil rights office with investigatory tools that can make your life expensive while the meaning of the law gets “clarified.”

What happened, in plain English

States regulate insurance. Some states require state-regulated plans to cover abortion (sometimes with limits around cost-sharing). The Weldon Amendment, meanwhile, is designed to stop governments from punishing certain health care entities because they will not pay for or cover abortion.

Now the federal government is telling those states: your mandate might be illegal if it does not leave enough room for opt-outs by insurers, plans, and potentially employers or sponsors. The next steps are investigations and information requests. This is not a courtroom ruling yet. It is a federal power move with an intake form.

The Orwell check:

When an agency calls something a “civil rights investigation,” I do the Orwell check. Are we protecting the weak from the strong, or handing the strong a nicer vocabulary for control? “Conscience protection” can mean defending a clinician from being forced into a procedure. It can also mean giving institutions and insurance intermediaries a policy veto that patients experience as a denial, a delay, or a surprise bill.

The Paine test and the liberty ledger

The Paine test: does this expand liberty, or concentrate power? If state mandates are too blunt, that is a real concern. But if the federal response is investigatory leverage to overrule state insurance policy, admit the purchase: centralized power.

Liberty ledger: plans, insurers, and possibly employers or sponsors gain room to refuse participation. Patients in those thirteen states risk losing uniform coverage promised under state law, even if abortion remains legal there. And the quiet loser is the public, watching major health policy swing on administrative interpretations.

So here is my question: if your health plan is going to be the battlefield for this conscience war, what guardrail would you demand first, and from which level of government?

I was raised to trust a library more than a podium. Libraries are where claims go to get cross-examined. Podiums are where claims go to get applause. So when Washington announces it has found a new cure for what ails us, I reach for my pencil, not my heart. In the committee-room air of American public health, every reform arrives wearing a friendly name tag and carrying a quiet tool belt.

This week, that tool belt is labeled nutrition. Which is not crazy. Chronic disease is eating the country alive, and we have trained doctors to memorize molecules while treating food like a lifestyle hobby. Still, in a town where power never met a good idea it could not franchise, I keep one question on the clipboard: are we improving medicine, or centralizing it?

What HHS and Education announced

On March 5, the Department of Health and Human Services and the Department of Education announced an initiative to increase nutrition education in medical schools, pointing to commitments from 53 medical schools across 31 states. The target is at least 40 hours of nutrition education, or a 40-hour competency equivalent, beginning in fall 2026. HHS also said it will dedicate $5 million through a multi-phase National Institutes of Health nutrition education challenge, and that Public Health Service officers will be required to complete nutrition-focused continuing education hours as part of their career development.

The Association of American Medical Colleges framed this as recognition of ongoing work and a push to embed evidence-based nutrition education across training. STAT reported participating schools agreed to steps such as assessing current curriculum, naming a faculty champion, and creating a public landing page describing how they will reach the 40-hour mark by fall 2026.

The Orwell check: “voluntary” and the hand on the doorknob

The administration has been careful to say this is not the federal government dictating a medical curriculum. That sentence is doing a lot of work.

The Washington Post reported HHS officials stressed the agreements are not mandatory and the event was celebratory, while also noting Secretary Robert F. Kennedy Jr. previously suggested schools without nutrition programs could risk losing federal funding, and that HHS directed medical education organizations to submit plans on embedding nutrition education efforts. The carrot is out front, but the stick has been publicly admired.

The Paine test and the liberty ledger

• What expands liberty: better training could mean more competent, practical nutrition counseling and less of the shrug-and-printout routine.
• What concentrates power: federal muscle near curricula, even in a salad-bar tie, invites definition fights over what counts as “evidence-based” and what “competency equivalent” really means.
• Who gets leaned on: schools that rely heavily on federal dollars, where autonomy can become a polite fiction.
• What else is at risk: trust, if nutrition education becomes another culture-war trench line.

The tradeoff: prevention, yes. Curriculum control, no.

I can hold two thoughts at once: nutrition belongs in medical training, and power needs guardrails. If this is truly voluntary, prove it with guardrails: publish criteria for “competency equivalent,” keep the NIH challenge insulated from political loyalty tests, make curriculum resources open, peer-reviewed, and auditable, and put in writing that schools will not be punished for good-faith disagreement so long as they can demonstrate outcomes and evidence-based instruction.

Nutrition education is a good idea. The question is whether we can accept a good idea without accepting a new lever of centralized control.

You can smell a regulatory panic from three aisles over, somewhere between the dusty civics textbooks and the court dockets nobody reads until the day something goes wrong. The pattern rarely changes: a hot new product, a fast market, a slow bureaucracy, and consumers learning the fine print after they have already signed up for autopay.

FDA sends 30 warning letters over marketing of compounded GLP-1 weight-loss drugs

On March 3, the Food and Drug Administration announced it had issued 30 warning letters to telehealth companies over what it described as false or misleading claims about compounded GLP-1 products advertised on their websites. The FDA said the big problems were marketing that implied compounded products were the same as FDA-approved drugs, and marketing that obscured where the drugs came from, including branding that could make consumers think the telehealth company itself was the compounder.

The agency also underlined a point that should not require underlining: compounded drugs are not FDA-approved, and they are not the same thing as FDA-approved generics. The FDA does not pre-review compounded drugs for safety, effectiveness, or quality before they are marketed. If you choose a compounded product, you should be doing it with your eyes open, not because a website sprinkled the word same around like parmesan.

Trade press coverage adds the procedural teeth: targeted firms are told to address the FDA’s concerns within a short window, and the agency warns it can pursue enforcement actions if they do not. Not a polite reminder. More like the librarian tapping the sign that says QUIET and also PLEASE RETURN THE BOOKS OR WE WILL CLOSE YOUR ACCOUNT.

What happened, in plain English

GLP-1 drugs have been a modern miracle for many patients, especially for diabetes and obesity. They have also been a modern mess in supply and pricing. That mess helped create a market for compounded versions, often distributed through telehealth pipelines that can move faster than your primary care office can answer the phone.

Compounding has a legitimate place in medicine, including when a patient needs a specific formulation or a shortage blocks access to the standard product. But it becomes a different creature when the business model is mass marketing a copycat and nudging the public into believing they are basically getting the branded product, just cheaper and faster.

The tradeoff: consumer protection vs. access

I want the FDA to crack down on misleading claims. Misleading drug marketing is not a partisan personality quiz. If a company is implying regulatory sameness where there is no FDA-reviewed sameness, that is a consumer-protection problem.

But I also want us to admit what makes this market possible. People are not chasing compounded GLP-1s because they enjoy regulatory gray zones. They are chasing them because the official route often costs too much, takes too long, or comes wrapped in insurance hurdles designed like an obstacle course built by someone who hates knees.

The Paine test, the Orwell check, and the liberty ledger

• The Paine test: truth-in-advertising enforcement can expand liberty by improving informed consent. But if enforcement becomes a substitute for fixing price-and-access reality, power concentrates and trust erodes.
• The Orwell check: watch the euphemisms, especially “personalization” and “same.” Language that blurs oversight and evidence is doing more work than it should.
• The liberty ledger: patients gain when disclosures are clear about what the product is, who made it, and what oversight exists. Patients lose if options shrink while FDA-approved options remain financially out of reach.

Guardrails that would make this feel less like theater

If we want more than a headline cycle: publish the warning letters in a searchable, readable way with plain-English summaries; focus enforcement on deception and unsafe practices, not lawful compounding for genuine clinical need; and push policy that targets the incentives driving people into gray markets, including drug pricing and coverage design.

So yes: police misleading marketing. But if Americans keep needing workarounds to obtain mainstream medications, the workarounds are not the scandal. The system is. Are we going to fix the price-and-access reality that created this GLP-1 gold rush, or just keep yelling at the prospectors?

I was in the kind of municipal building where the air smells like paper, rubber stamps, and decisions made at 11:58 p.m. The bulletin board was pure civic routine: a lost cat, a zoning notice, and a laminated warning about something that is always, somehow, for our safety.

Then I read about glass. Not metaphorical glass, like transparency. Actual glass. The kind that does not belong in dinner.

USDA recall update: nearly 37 million pounds

On March 3, the U.S. Department of Agriculture’s Food Safety and Inspection Service said Ajinomoto Foods North America expanded a recall tied to possible glass contamination. The update added roughly 33.6 million pounds of ready-to-eat and not-ready-to-eat frozen products, bringing the total to about 36.99 million pounds.

The affected items include chicken and pork fried rice, ramen, and shu mai dumplings sold under multiple brand names, including Ajinomoto, Kroger, Ling Ling, Tai Pei, and Trader Joe’s. The products were produced from October 21, 2024 through February 26, 2026, shipped to retail locations nationwide, and some were exported to Canada and Mexico. As of reports citing the FSIS update, no confirmed injuries had been reported.

Ajinomoto, after investigating consumer complaints, determined that carrots used as an ingredient were the likely source of the glass contamination. Yes, carrots. The orange stick you hand to toddlers as a peace offering. In 2026, that carrot can apparently empty freezers across a continent.

This expanded action stacks on top of the earlier February 19 FSIS-announced recall of about 3.37 million pounds of frozen chicken fried rice products, also tied to possible glass. The plotline is familiar: complaint, investigation, expansion, and that polite modern phrase that means everyone is scrambling: voluntary recall.

The tradeoff: convenience dinners, centralized risk

We built a food system optimized for speed and sameness. That is not a moral failing. It is the logical endpoint of busy lives and long commutes.

But convenience comes with a shadow invoice. When production is centralized, a single ingredient runs through an industrial river. If something goes wrong upstream, it does not stay local. It goes national, sometimes international, before the first worried customer figures out why their mouth feels like a hardware aisle.

And the public is asked to manage the last mile of safety with the least amount of information: check your freezer, find the establishment number, compare dates, do not eat, return or discard. It is like being handed a court docket and told to practice law in the parking lot.

Liberty ledger, Orwell check, Paine test

The liberty ledger: the public gains notice, but also inherits paperwork. People with the least slack are asked to throw away food, drive back to a store, or gamble that their particular bag is not the one with the invisible hazard.

The Orwell check: food safety language is soothing: voluntary, precautionary, out of an abundance of caution. Sometimes it is honest. Sometimes it is a whisper while the building is on fire.

The Paine test: does the response expand liberty or concentrate power? A strong food safety system expands liberty by letting people buy food without becoming part-time forensic accountants. A lazy response concentrates power by keeping the industrial pipeline opaque while shifting risk management onto households.

So yes, demand the boring stuff that prevents the dramatic stuff: fund inspection and modern traceability tools with strict privacy guardrails, publish clearer recall data normal people can use, insist on audits that have teeth, and make refunds simple and proactive. We can have convenience and safety, but we cannot keep pretending a mega-scale food system will police itself forever. If a carrot can do this much damage, what exactly are we waiting for before we tighten the guardrails?

I have seen this routine in the burnt-coffee committee rooms: a speech about “lean government,” followed by a purchase order for a brand-new bureaucracy. Medicaid is supposed to be health care. The current push is to build a machine that measures virtue with a timesheet.

Spend millions to “save” money

The Associated Press reported this week that states face large up-front costs to comply with Medicaid eligibility mandates tied to work or similar activities. The irony is not subtle: to prove you are serious about saving money, you first spend a lot of it.

Based on the AP’s review of budget projections in more than 25 states, technology upgrades and extra staffing are likely to exceed $1 billion. A $200 million federal allotment is already flowing to help implementation, but it does not cover the whole project.

Who gets targeted, and how often they must prove it

In most states, the requirements described would apply to adults ages 19 to 64 without young children whose incomes are above the typical eligibility cutoff. They would need to show at least 80 hours a month of work or community service, or enroll at least half-time as a student. Eligibility reviews would shift from annual to every six months, meaning the paperwork clock ticks twice as often.

Washington says the point is savings. The Congressional Budget Office estimate cited by the AP projects $388 billion in federal savings over a decade, alongside 6 million fewer people with health insurance. That is the tradeoff in plain numbers.

The practical snag: states do not have the data

Most states do not currently collect employment or education information from Medicaid participants, so they must build portals, redesign eligibility systems, set up data checks, train staff, and hire contractors. Examples cited include:

• Missouri: a fast-tracked $32 million appropriation and about 120 workers costing $12.5 million.
• Maryland: more than $32 million in combined state and federal spending.
• Kentucky: more than $46 million.
• Colorado: more than $51 million.
• Arizona: $65 million and roughly 150 additional staff.

Meanwhile, key exceptions, including who qualifies as medically frail, are not planned to be defined until rules due in June. States are being asked to pour a foundation before they receive the blueprint.

The Orwell check and the liberty ledger

My Orwell check: the language comes in soft. Work requirements become “community engagement.” Disenrollment becomes “program integrity.” Extra paperwork becomes “dignity.” But the system runs on compliance.

Liberty ledger: vendors and contractors get a new market; agencies get new systems and headcount; politicians get a tidy talking point. The people most likely to lose coverage are those with unstable hours, limited internet access, or health problems that are real but hard to document neatly, especially while states wait on the medically frail definition.

Georgia is currently the only state requiring some Medicaid recipients to work under its Pathways to Coverage program. A Government Accountability Office report found Georgia spent $54.2 million on administrative costs between October 2020 and March 2025, mostly financed by federal dollars.

The Paine test and the tradeoff

The Paine test: does this expand liberty, or concentrate power? Conditioning health coverage on a reporting regime concentrates power and turns coverage into a bureaucratic correctness contest. If the goal is savings, the public deserves hard numbers: projected costs, vendor contracts, error rates, and appeal timelines, not slogans. And with federal penalties for too many Medicaid payment errors starting in October 2029, states will feel pressure to overbuild controls now.

I spent part of yesterday in that classic American policy workshop: a fluorescent-lit corner of the public library, Federal Register open, printer toner in the air, civic dread on the menu. In my head: a senior with a walker, a kid with braces, a veteran with a CPAP. On screen: Washington trying to stop scams without jamming up care.

What CMS did (and when)

CMS imposed a six-month, nationwide moratorium on new Medicare enrollments for certain durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) suppliers, specifically the supplier category it calls medical supply company suppliers. The notice says it takes effect February 27, 2026 and applies across the United States, including territories and the District of Columbia.

• New businesses whose principal function is furnishing DMEPOS supplies cannot newly enroll under the covered supplier types during the moratorium.
• Existing enrolled suppliers that need a new initial enrollment (for example, a new practice location that requires separate enrollment) also hit a locked door for six months.
• Applications received by contractors before the effective date are not supposed to be swept into the ban.

CMS lists seven affected supplier types, all variations of “medical supply company,” including versions staffed with orthotics, pedorthics, prosthetics, combinations of those, and versions with a registered pharmacist or a respiratory therapist. CMS says it will closely screen applications during the moratorium to stop would-be medical supply companies from slipping in through another category, and it explicitly mentions site visits and online research. It also warns about long reapplication or reenrollment bars and referrals when suppliers submit false or misleading information.

The Orwell check: “moratorium” is a ban with nicer shoes

“Moratorium” is the polite noun. “Temporary” is the comforting adjective. Together they read like a sweater you put on so you do not notice the handcuffs.

Yes, CMS points to authority to impose temporary enrollment moratoria when it determines there is significant potential for fraud, waste, or abuse, and it has to explain itself in a Federal Register notice. That is the civics-textbook version. The lived version is a nationwide enrollment ban, even a narrow one, is a big lever.

The tradeoff and the liberty ledger

CMS frames this as a fraud move, not a benefit cut: existing suppliers can keep billing. Other kinds of suppliers that furnish DMEPOS but do not have DMEPOS as their principal function (like pharmacies and hospitals) are not the target. CMS also leaves room for states to decide how, or whether, to mirror a similar moratorium in Medicaid and CHIP.

Who gains freedom? Beneficiaries and taxpayers, if fewer scams get through. Honest providers, if scammers stop undercutting the market. Who loses freedom? Clean new entrants, for six months, and communities with thin supplier networks that rely on competition and choice. And the system takes on more executive discretion, especially because the notice acknowledges the moratorium can be extended in six-month increments.

Guardrails worth demanding

• Publish monthly metrics that justify the moratorium and track collateral damage.
• Provide a clear, fast appeal and correction path for legitimate suppliers caught in gray zones.
• Congress should demand oversight review from inspectors general and GAO on whether a nationwide moratorium beats more targeted tools.
• Put an exit ramp in writing: a public standard for lifting the moratorium, and real specificity for any extension.

Fraud is a tax on care. But so is unaccountable power. Are we going to demand the guardrails now, or pretend “temporary” always means what it says?

I was in a library once, thumbing through a dusty local-court digest, when it hit me how much of American life is decided by people you never meet using rules you never see. Not a conspiracy. A filing system. In healthcare, the filing system has a co-pay.

What the FDA did (in public, on the record)

On February 25, 2026, the Food and Drug Administration approved Dupixent (dupilumab) for adults and children ages 6 and up with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. The FDA calls it the first approval for the condition.

AFRS is not your garden-variety stuffy-nose season. The FDA describes it as an uncommon, chronic sinus inflammation driven by an allergic reaction to fungi in the sinuses, with thick, sticky mucus. It can include expansion of the sinuses and erosion of surrounding bone, and in severe cases can push toward the eye area or brain. At that point your body stops being a body and starts being a construction site.

The FDA says the approval was supported by a 52-week study in patients 6 years and older. The agency points to improvements on CT scan scoring for sinus opacification, plus improvements in measures like nasal polyp size, congestion, and sense of smell. It also highlights reduced need for systemic corticosteroids and sinus surgery compared with placebo, and notes the safety profile looked consistent with what is already known for the drug.

That is the part I can respect: the referee blew the whistle, dated the page, and made a new play legal.

The tradeoff: progress paid for with paperwork and privacy

Here is the part that never makes the celebratory press release. In modern American medicine, FDA approval is often the start of the argument, not the end. The real gate swings on coverage, prior authorization, and the fine print of “medical necessity.”

And those gates are built out of patient data. If you want a high-cost biologic, the system often wants a biography:

• Imaging
• Procedure history
• Medication history
• Symptoms translated into billing codes

The approved indication includes a history of sino-nasal surgery. That is clinically meaningful, and also administratively irresistible. It turns your chart into a passport that has to be stamped, photocopied, and re-stamped until you either get the drug or run out of time.

The Orwell check: when delay wears a lab coat

Listen to the euphemisms and you can hear the power moving: “utilization management,” “benefits determination,” “step therapy,” “site of care optimization.” Translate it and a lot of it reads: prove you are sick enough, again, to someone who will not meet you.

The FDA did its job in public. The payer side too often does its job in private, with criteria you only see after you have been denied. That is a due process problem dressed up as a customer-service issue.

The liberty ledger (who gains, who loses)

• Patients gain a new, FDA-approved option that could mean fewer surgeries or fewer courses of systemic steroids.
• Clinicians gain another tool authorized for the problem at hand, which can matter when coverage fights multiply.
• Insurers and plan administrators gain a clearer box to build policies around, for better or worse.
• The public gains the possibility of fewer repeat surgeries and complications, and inherits the bill and the temptation to ration through delay.

The approval expands the menu. The fight is whether the menu becomes a meal or just a laminated tease.

The Paine test, and the guardrails that would make this real

The Paine test is simple: does the next phase expand a patient’s practical freedom to get appropriate care, or concentrate power in the hands of whoever controls the paperwork?

• Transparency: coverage criteria should be public, plain-language, and stable.
• Speed with teeth: appeals should move on timelines that match a patient’s life; when deadlines are missed, the default should not be “wait longer.”
• Data minimization: request the narrowest slice of information necessary, not a full medical autobiography.
• Oversight: treat prior authorization and documentation demands like the quasi-judicial system they are.

The FDA did the public part. Now the rest of government should do the boring part: rules, audits, enforcement, sunlight. Because if a life-changing therapy exists on paper but not in practice, we have not solved a medical problem. We have just invented a new reason to stand in line.

So here is my question: should access to an FDA-approved treatment hinge more on clinical need, or on how much private information you are willing to surrender to prove you deserve it?